Adicet Bio

Adicet Bio Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Adicet Bio (ACET) as of Nov 2, 2026 is 1.48. In the previous year, Net Debt to Free Cash Flow Ratio was 1.70 — a change of -12.86% (lower).

Net Debt/FCF

1.48

YoY

-12.86%

Last updated:

Net Debt to Free Cash Flow Ratio of Adicet Bio is 2025 1.48 . Net Debt to Free Cash Flow Ratio of Adicet Bio was 2024 1.70 . It decreases by -12.86% lower compared to the previous year.

The Adicet Bio Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
5.51 USD
Jan 1, 2019
-1.79 USD
Jan 1, 2020
1.72 USD
Jan 1, 2021
4.00 USD
Jan 1, 2022
3.84 USD
Jan 1, 2023
1.41 USD
Jan 1, 2024
1.70 USD
Jan 1, 2025
1.48 USD
The Adicet Bio Net Debt/FCF history
YEARNet Debt/FCFYoY
1.48-12.86%
1.70+20.36%
1.41-63.23%
3.84-3.96%
4.00+133.38%
1.72-196.09%
-1.79-132.42%
5.51-121.26%
-25.90-491.69%
6.61+117.39%
3.04+20.23%
2.53—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adicet Bio Stock analysis

What does Adicet Bio do? Adicet Bio, Inc. develops off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases, focusing on engineered gamma delta T cells with chimeric antigen receptors and T cell receptor-like antibodies. The company's pipeline includes ADI-001 targeting CD20, ADI-002 targeting glypican 3 protein (GPC3), and ADI-00x for solid tumors and hematological indications. These therapies aim to enable selective tumor targeting, facilitate immune responses, and improve patient persistence. The company generates revenue through the development and potential commercialization of its pipeline products, with ADI-001, ADI-002, and ADI-00x representing key therapeutic candidates for oncology markets. Adicet Bio, Inc. is a biotechnology firm targeting the oncology sector with its gamma delta T cell therapies, designed to address unmet medical needs in cancer treatment. The company's product portfolio consists of ADI-001, ADI-002, and ADI-00x, each targeting specific antigens for tumor targeting. ADI-001 focuses on CD20, ADI-002 on GPC3, and ADI-00x on solid tumors and hematological conditions. These therapies are developed for potential commercialization in the biopharmaceutical market, where pharmaceutical companies and healthcare providers may purchase or license the therapies for patient treatment. The company's revenue model relies on the progression of its pipeline products through clinical development and eventual market entry. ADI-001, ADI-002, and ADI-00x are the primary products driving potential revenue, with ADI-001 and ADI-002 currently in development for specific cancer indications. The firm's focus on allogeneic therapies positions it to serve patients requiring off-the-shelf treatments, differentiating from autologous approaches. Adicet Bio, Inc. aims to secure partnerships or direct sales for its therapies, targeting oncology specialists and hospitals as key buyers in the healthcare ecosystem. Adicet Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Adicet Bio stock

Net Debt to Free Cash Flow Ratio of Adicet Bio is 1.48 in 2025.

Net Debt to Free Cash Flow Ratio of Adicet Bio changed from 1.70 to 1.48, representing a -12.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Adicet Bio since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Adicet Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Adicet Bio

All Key Metrics — Adicet Bio